SeekGene Raises Tens of Millions CNY in Pre-A Round Financing

According to med.sina.com, SeekGene has completed its Pre-A financing of tens of millions CNY, led by Delian Capital. The proceeds of the round will be mainly used for the marketing of the single-cell sequencing kit and the R&D of single-cell detection technologies. SeekGene obtained its angel round financing from Zhenfund in October 2018.

Founded in 2015, SeekGene is a technology-driven biotechnology enterprise, focusing on the development of single-cell sorting detection technology and clinical application. The high-throughput single-cell transcriptome sequencing kit independently developed by the company has reached the world's leading level in performance. This kind of product has great features of flexibility, simplicity, economy, and accuracy, which can improve the clinical transformation and application of single-cell sequencing technology.

The company will continue to provide new perspectives and solutions for disease screening and drug discovery through high-throughput single-cell sequencing technology in the field of adaptive cellular immunity to monitor the human immune system with higher resolution, at the level of protein transcription and synthesis.

Founded in 2011, Delian Capital specializes in the field of tech-driven industries such as high-end manufacturing, cutting-edge technologies, and healthcare. Its investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterprise services, healthcare, etc.

ZhenFund is a seed-stage focused venture fund with over $1 billion under management since founded in 2011 by Bob Xu and Victor Wang, in collaboration with Sequoia Capital China. Bob and Victor previously co-founded New Oriental (NYSE: EDU), one of the world's largest education conglomerates.